LENZ Therapeutics, Inc. (LENZ) SEC filings

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3046% below fair value

$4.13+0.04 (+0.98%)

Close on Nov 13, 2026Market cap $129.77MP/E –Yield –

SEC filings

40 of LENZ Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 3, 2026	SEC EDGAR
Current report	8-K	Oct 28, 2026	Oct 28, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Aug 11, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 11, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 11, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 12, 2026	Apr 28, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 24, 2026	SEC EDGAR
Current report	8-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Current report	8-K	Jan 7, 2026	Jan 7, 2026	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 12, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Oct 8, 2025	Oct 8, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Current report	8-K	Jul 31, 2025	Jul 31, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jun 10, 2025	Jun 10, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 10, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Apr 15, 2025	Apr 15, 2025	SEC EDGAR
Current report	8-K	Apr 4, 2025	Apr 4, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 19, 2025	SEC EDGAR
Current report	8-K	Mar 19, 2025	Mar 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Oct 27, 2024	Oct 28, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	Aug 14, 2024	Aug 14, 2024	SEC EDGAR
Current report	8-K	Aug 12, 2024	Aug 12, 2024	SEC EDGAR
Current report	8-K	Jul 14, 2024	Jul 15, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Current report	8-K	Apr 3, 2024	Apr 3, 2024	SEC EDGAR
Current report	8-K	Mar 21, 2024	Mar 22, 2024	SEC EDGAR
Current report	8-K	Mar 19, 2024	Mar 19, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in LENZ Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-29 reverse split on May 8, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LENZ.

Compare: LENZ vs ACOG · LENZ vs SCLX · LENZ vs VYGR · LENZ vs LCTX · LENZ vs OCUL

Revenue growth329.5% · median -14.8%

Gross margin86.9% · median 92.9%

Operating margin-631.7% · median -450.1%

Net margin-586.7% · median -416.3%

Company	Revenue	Growth
OCUL	$50.38M	-9.7%
SCLX	$31.61M	-28.5%
VYGR	$25.11M	-19.8%
LENZ	$21.48M	+329.5%
ACOG	$20.20M	–
LCTX	$10.84M	+0.2%

Company

Next earnings (est.): Mar 23, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 152
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1815776

Advertisement
300 × 250

See a number that looks wrong?